174 related articles for article (PubMed ID: 38474294)
1. Different Patterns of Platinum Resistance in Ovarian Cancer Cells with Homologous Recombination Proficient and Deficient Background.
Chiappa M; Guffanti F; Grasselli C; Panini N; Corbelli A; Fiordaliso F; Damia G
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474294
[TBL] [Abstract][Full Text] [Related]
2. Differential contributory roles of nucleotide excision and homologous recombination repair for enhancing cisplatin sensitivity in human ovarian cancer cells.
Wang QE; Milum K; Han C; Huang YW; Wani G; Thomale J; Wani AA
Mol Cancer; 2011 Mar; 10():24. PubMed ID: 21385444
[TBL] [Abstract][Full Text] [Related]
3. MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib.
Whicker ME; Lin ZP; Hanna R; Sartorelli AC; Ratner ES
BMC Cancer; 2016 Jul; 16():550. PubMed ID: 27465688
[TBL] [Abstract][Full Text] [Related]
4. Combinations of ATR, Chk1 and Wee1 Inhibitors with Olaparib Are Active in Olaparib Resistant
Chiappa M; Guffanti F; Anselmi M; Lupi M; Panini N; Wiesmüller L; Damia G
Cancers (Basel); 2022 Apr; 14(7):. PubMed ID: 35406579
[TBL] [Abstract][Full Text] [Related]
5. Non-specific chemical inhibition of the Fanconi anemia pathway sensitizes cancer cells to cisplatin.
Jacquemont C; Simon JA; D'Andrea AD; Taniguchi T
Mol Cancer; 2012 Apr; 11():26. PubMed ID: 22537224
[TBL] [Abstract][Full Text] [Related]
6. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
Schmidt W; Chaney SG
Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
[TBL] [Abstract][Full Text] [Related]
7. A Functional Homologous Recombination Assay Predicts Primary Chemotherapy Response and Long-Term Survival in Ovarian Cancer Patients.
Tumiati M; Hietanen S; Hynninen J; Pietilä E; Färkkilä A; Kaipio K; Roering P; Huhtinen K; Alkodsi A; Li Y; Lehtonen R; Erkan EP; Tuominen MM; Lehti K; Hautaniemi SK; Vähärautio A; Grénman S; Carpén O; Kauppi L
Clin Cancer Res; 2018 Sep; 24(18):4482-4493. PubMed ID: 29858219
[No Abstract] [Full Text] [Related]
8. Evidence for different mechanisms of 'unhooking' for melphalan and cisplatin-induced DNA interstrand cross-links in vitro and in clinical acquired resistant tumour samples.
Spanswick VJ; Lowe HL; Newton C; Bingham JP; Bagnobianchi A; Kiakos K; Craddock C; Ledermann JA; Hochhauser D; Hartley JA
BMC Cancer; 2012 Sep; 12():436. PubMed ID: 23020514
[TBL] [Abstract][Full Text] [Related]
9. [Establishment and biological characteristics of a platinum-resistance nude mouse model in epithelial ovarian cancer].
Shi L; Yu H; Zhang W; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):523-30. PubMed ID: 25327735
[TBL] [Abstract][Full Text] [Related]
10. The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer.
Yan S; Xuan J; Brajanovski N; Tancock MRC; Madhamshettiwar PB; Simpson KJ; Ellis S; Kang J; Cullinane C; Sheppard KE; Hannan KM; Hannan RD; Sanij E; Pearson RB; Chan KT
Br J Cancer; 2021 Feb; 124(3):616-627. PubMed ID: 33173151
[TBL] [Abstract][Full Text] [Related]
11. CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors.
Lu X; He Y; Johnston RL; Nanayakarra D; Sankarasubramanian S; Lopez JA; Friedlander M; Kalimutho M; Hooper JD; Raninga PV; Khanna KK
J Exp Clin Cancer Res; 2022 Dec; 41(1):355. PubMed ID: 36539830
[TBL] [Abstract][Full Text] [Related]
12. Panobinostat sensitizes cyclin E high, homologous recombination-proficient ovarian cancer to olaparib.
Wilson AJ; Sarfo-Kantanka K; Barrack T; Steck A; Saskowski J; Crispens MA; Khabele D
Gynecol Oncol; 2016 Oct; 143(1):143-151. PubMed ID: 27444036
[TBL] [Abstract][Full Text] [Related]
13. Cellular pharmacology of cis and trans pairs of platinum complexes in cisplatin-sensitive and -resistant human ovarian carcinoma cells.
O'Neill CF; Hunakova L; Kelland LR
Chem Biol Interact; 1999 Nov; 123(1):11-29. PubMed ID: 10597899
[TBL] [Abstract][Full Text] [Related]
14. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
O'Neill CF; Koberle B; Masters JR; Kelland LR
Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
[TBL] [Abstract][Full Text] [Related]
15. Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells.
Gaikwad SM; Thakur B; Sakpal A; Singh RK; Ray P
Int J Biochem Cell Biol; 2015 Apr; 61():90-102. PubMed ID: 25681684
[TBL] [Abstract][Full Text] [Related]
16. Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer.
Lambrechts S; Smeets D; Moisse M; Braicu EI; Vanderstichele A; Zhao H; Van Nieuwenhuysen E; Berns E; Sehouli J; Zeillinger R; Darb-Esfahani S; Cacsire Castillo-Tong D; Lambrechts D; Vergote I
Eur J Cancer; 2016 Jan; 53():51-64. PubMed ID: 26693899
[TBL] [Abstract][Full Text] [Related]
17. VLX600 Disrupts Homologous Recombination and Synergizes with PARP Inhibitors and Cisplatin by Inhibiting Histone Lysine Demethylases.
Ekstrom TL; Pathoulas NM; Huehls AM; Kanakkanthara A; Karnitz LM
Mol Cancer Ther; 2021 Sep; 20(9):1561-1571. PubMed ID: 34224364
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel and SN-38 overcome cisplatin resistance of ovarian cancer cell lines by down-regulating the influx and efflux system of cisplatin.
Komuro Y; Udagawa Y; Susumu N; Aoki D; Kubota T; Nozawa S
Jpn J Cancer Res; 2001 Nov; 92(11):1242-50. PubMed ID: 11714450
[TBL] [Abstract][Full Text] [Related]
19. Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer.
Gupta VG; Hirst J; Petersen S; Roby KF; Kusch M; Zhou H; Clive ML; Jewell A; Pathak HB; Godwin AK; Wilson AJ; Crispens MA; Cybulla E; Vindigni A; Fuh KC; Khabele D
Gynecol Oncol; 2021 Jul; 162(1):163-172. PubMed ID: 33867143
[TBL] [Abstract][Full Text] [Related]
20. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D
Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]